Hematologic Malignancy
Adult Grade III Lymphomatoid Granulomatosis
CI-CAN-00004375Explore in graph →
Hematologic1 active trials
- NCIt
- C115150
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004375Explore in graph →
Clinical trials
71 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (18)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00891072 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jul 2, 2015source: clinicaltrials